The secondary efficacy end-points were differences in daily mean : ( i ) voiding frequency at @ and @weeks ; ( ii ) urgency frequency ; ( iii ) urgency incontinence frequency ; ( iv ) incontinence frequency ; ( v ) nocturia frequency ; and ( vi ) quality of life score .